Clinical Trial Detail

NCT ID NCT01437566
Title Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

GDC-0980

Fulvestrant

Pictilisib

Age Groups: adult

Additional content available in CKB BOOST